Study of Ataluren (PTC124®) in Hemophilia A and B



Status:Archived
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:August 2009
End Date:February 2011

Use our guide to learn which trials are right for you!

A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B


Hemophilia A (HA) and hemophilia B (HB) are inherited bleeding disorders caused by mutations
in the gene for factor VIII (FVIII) and factor IX (FIX), respectively. These proteins are
essential for blood clotting. The lack of FVIII/FIX can produce bleeding episodes that cause
damage of the bone, muscles, joints, and tissues. A specific type of mutation, called a
nonsense (premature stop codon) mutation, is the cause of the disease in approximately
10-30% of patients with hemophilia and results in severe manifestations. Ataluren (PTC124)
is an orally delivered, investigational drug that acts to overcome the effects of the
premature stop codon, potentially enabling the production of functional FVIII/FIX. This
study is a Phase 2a trial evaluating the safety and efficacy of ataluren in patients with HA
or HB due to a nonsense mutation. The main purpose of this study is to understand whether
ataluren can safely increase FVIII/FIX activity levels.


In this study, patients with hemophilia A or hemophilia B due to a nonsense mutation will be
treated with an investigational drug called ataluren (PTC124). Evaluation procedures to
determine if a patient qualifies for the study will be performed within 14 days prior to the
start of treatment. Eligible patients who elect to enroll in the study will then participate
in a 28-day treatment period. Within the 28-day period, ataluren (PTC124) treatment will be
taken 3 times per day with meals for 14 days at a dose of 10 mg/kg (morning), 10 mg/kg
(midday) and 20 mg/kg (evening); there will then be an interval of approximately 14 days
without treatment. During the study, ataluren (PTC124) efficacy, safety, and
pharmacokinetics will be evaluated periodically with measurement of FVIII/FIX activity and
inhibitor levels, other blood tests, and urinalysis.


We found this trial at
7
sites
Nashville, Tennessee 37232
?
mi
from
Nashville, TN
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
2001 86th Street West
Indianapolis, Indiana 46260
(317) 338-2345
St. Vincent Indianapolis Hospital At St.Vincent Indianapolis, everything we do begins with a focus on...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Brooklyn, New York 11203
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
?
mi
from
Peoria, IL
Click here to add this to my saved trials
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Worcester, Massachusetts 01605
?
mi
from
Worcester, MA
Click here to add this to my saved trials